Требования к антигипертензивной терапии у больных сахарным диабетом и хронической болезнью почек: взгляд с позиций новых европейских рекомендаций 2018 г.
Требования к антигипертензивной терапии у больных сахарным диабетом и хронической болезнью почек: взгляд с позиций новых европейских рекомендаций 2018 г.
Остроумова О.Д., Голобородова И.В. Требования к антигипертензивной терапии у больных сахарным диабетом и хронической болезнью почек: взгляд с позиций новых европейских рекомендаций 2018 г. Consilium Medicum. 2018; 20 (12): 74–79. DOI: 10.26442/20751753.2018.12.180157
________________________________________________
Ostroumova O.D., Goloborodova I.V. Antihypertensive therapy in patients with diabetes mellitus and chronic kidney disease specifications: the perspective of modern European guidelines 2018. Consilium Medicum. 2018; 20 (12): 74–79. DOI: 10.26442/20751753.2018.12.180157
Требования к антигипертензивной терапии у больных сахарным диабетом и хронической болезнью почек: взгляд с позиций новых европейских рекомендаций 2018 г.
Остроумова О.Д., Голобородова И.В. Требования к антигипертензивной терапии у больных сахарным диабетом и хронической болезнью почек: взгляд с позиций новых европейских рекомендаций 2018 г. Consilium Medicum. 2018; 20 (12): 74–79. DOI: 10.26442/20751753.2018.12.180157
________________________________________________
Ostroumova O.D., Goloborodova I.V. Antihypertensive therapy in patients with diabetes mellitus and chronic kidney disease specifications: the perspective of modern European guidelines 2018. Consilium Medicum. 2018; 20 (12): 74–79. DOI: 10.26442/20751753.2018.12.180157
В данной статье с позиций современных европейских рекомендаций 2018 г. рассмотрен вопрос об особенностях антигипертензивной терапии (АГТ) у больных сахарным диабетом 2-го типа и хронической болезнью почек. Отражено место блокатора кальциевых каналов нитрендипина и тиазидоподобного диуретика индапамида в структуре АГТ, обосновано их преимущество для использования в составе комбинированной АГТ у таких больных.
In the present article antihypertensive therapy (AT) properties in patients with type 2 diabetes mellitus and chronic kidney disease are discussed from the perspective of modern European guidelines 2018. Calcium channel blocker nitrendipine and thiazid-like diuretic indapamide place in AT is discussed and their advantages of use in combination therapy in these patients are presented.
1. NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet 2017; 389 (10064): 37–55. DOI: 10.1016/S0140-6736(16)31919-5
2. Chow CK, Teo KK, Rangarajan S et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310 (9): 959–68. DOI: 10.1001/jama.2013.184182
3. Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217–23. DOI: 10.1016/S0140-6736(05)70151-3
4. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; (00): 1–98. DOI: 10.1093/eurheartj/ehy339
5. Forouzanfar MH, Liu P, Roth GA et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. JAMA 2017; 317 (2): 165–82. DOI: 10.1001/jama.2016.19043
6. Общероссийская общественная организация Ассоциация врачей общей практики (семейных врачей). Секция «Сочетанные патологии». Коморбидная патология в клинической практике. Клинические рекомендации. Кардиоваск. терапия и профилактика. 2017; 16 (6): 5–56. DOI: 10.15829/1728-8800-2017-6 / Obshcherossiiskaia obshchestvennaia organizatsiia Assotsiatsiia vrachei obshchei praktiki (semeinykh vrachei). Sektsiia "Sochetannye patologii". Komorbidnaia patologiia v klinicheskoi praktike. Klinicheskie rekomendatsii. Kardiovask. terapiia i profilaktika. 2017; 16 (6): 5–56. DOI: 10.15829/1728-8800-2017-6 [in Russian]
7. Дедов И.И., Шестакова М.В., Викулова О.К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический анализ по данным Федерального регистра сахарного диабета. Сахарный диабет. 2017; 1 (20): 13–41. / Dedov I.I., Shestakova M.V., Vikulova O.K. Epidemiologiia sakharnogo diabeta v Rossiiskoi Federatsii: kliniko-statisticheskii analiz po dannym Federal'nogo registra sakharnogo diabeta. Sakharnyi diabet. 2017; 1 (20): 13–41. [in Russian]
8. IDF Diabetes Atlas, 8th edition. Brussels: International Diabetes Federation; 2017. Available from: https://www.idf.org/e-library/epidemiologyresearch/diabetes-atlas/134-idf-diabetes-atlas-8th-edition. html.
9. Davy KP, Hall JE. Obesity and hypertension: two epidemics or one? Am J Physiol Regul Integr Comp Physiol 2004; 286 (5): 803–13.
10. Морозова Т.Е. Особенности антигипертензивной терапии у пациентов с метаболическим синдромом и сахарным диабетом. Справочник поликлинического врача. 2006; 8: 25–31. / Morozova T.E. Osobennosti antigipertenzivnoi terapii u patsientov s metabolicheskim sindromom i sakharnym diabetom. Spravochnik poliklinicheskogo vracha. 2006; 8: 25–31. [in Russian]
11. Kaur J. A comprehensive Review on Metabolic Syndrome. Cardiol Res Practice 2014. DOI: org/10.1155/2014/943162
12. Samson SL, Garber AJ. Metabolic syndrome. Endocr Metab Clin North Am 2014; 43 (1): 1–23. PMID: 24582089
13. Российское медицинское общество по артериальной гипертонии (РМОАГ). Рекомендации по ведению больных метаболическим синдромом. Клинические рекомендации. М., 2013. / Rossiiskoe meditsinskoe obshchestvo po arterial'noi gipertonii (RMOAG). Rekomendatsii po vedeniiu bol'nykh metabolicheskim sindromom. Klinicheskie rekomendatsii. M., 2013. [in Russian]
14. Nwaneri C, Cooper H, Bowen-Jones D. Mortality in type 2 diabetes mellitus: magnitude of the evidence from a systematic review and meta-analysis. Br J Diabet Vasc Dis 2013; 4 (13): 192–207. DOI: 10.1177/1474651413495703
15. Sarwar N, Gao P, Seshasai SR et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215–22. DOI: 10.1016/S0140-6736(10)60484-9
16. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979; 241: 2035–8.
17. Miettinen H, Lehto S, Salomaa V et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998; 21 (1): 69–75.
18. Multiple Risk Factor Intervention Trial Research Group: relationship between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial. Prev Med 1986; 15: 254–73.
19. Haffner M, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with 2 diabetes and in nondiabetic subjects with and without prior myocardial infaction. N Eng J Med 1998; 339: 229–34.
20. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53. DOI: 10.1016/S0140-6736(98)07019-6
21. Блокаторы кальциевых каналов: описание фармакологической группы в Энциклопедии РЛС. Регистр лекарственных средств России, РЛС. URL: https://www.rlsnet.ru/fg_index_id_215.htm / Blokatory kal'tsievykh kanalov: opisanie farmakologicheskoi gruppy v Entsiklopedii RLS. Registr lekarstvennykh sredstv Rossii, RLS. URL: https://www.rlsnet.ru/fg_index_id_215.htm [in Russian]
22. Fagard RH, Staessen JA. Treatment of isolated systolic hypertension in the elderly: the Syst-Eur trial. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Clin Exp Hypertens 1999; 21 (5–6): 491–7. PMID: 10423075
23. Wang JG, Staessen JA, Gong L, Liu L. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med 2000; 160 (2): 211–20. PMID: 10647760
24. Tuomilehto J, Rastenyte D, Birkenhager WH et al. Effects of calcium channel blockers in older patients with diabetes and systolic hypertension. Eng J Med 1999; 340 (9): 677–84.
25. Farský S, Strišková A, Borčin M. Hypertension Treatment in Patients with Metabolic Syndrome and/or Type 2 Diabetes Mellitus: Analysis of the Therapy Effectivity and the Therapeutic Inertia in Outpatient Study. Card Res Practice 2018; 2018 (1): 8387613. DOI: 10.1155/2018/8387613
26. Rohr G, Reimnitz P, Blanke P. Treatment of hypertensive emergency. Comparison of a new dosage form of the calcium antagonist nitrendipine with nifedipine capsules. Int Care Med 1994; 20 (4): 268–71. PMID: 8046120
27. Mancini M, Marotta T, Ferrara LA. Metabolic neutrality in nitrendipine therapy. J Cardiovasc Pharmacol Ther 1991; 18 (1): 3–30.
28. Ferrara LA, Marotta T. Nitrendipine and metabolic balance. J Cardiovasc Pharmacol Ther 1991; 18 (5): 19–21.
29. Grandinetti O, Feraco E. Middle term evaluation of amlodipine vs. nitrendipine: efficacy, safety and metabolic effects in elderly hypertensive patients. Clin Exp hypertens 1993; 15 (1): 197–210. PMID: 8513310
30. Roush GC, Ernst ME, Kostis JB et al. Head-to-Head Comparisons Hydrochlorothiazide Indapamide and Chlorthalidone: Antihypertensive and Metabolic Effects. Hypertension 2015; 65 (5): 1041–6. DOI: 10.1161/hypertensionaha.114.05021
31. Gerstein HC, Mann JF, Yi Q et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. J Am Med Assoc 2001; 286 (4): 421–6. PMID: 11466120
32. Malhotra R, Nguyen HA, Benavente O et al. Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5: a systematic review and meta-analysis. J Am Med Assoc Int Med 2017; 177: 1498–505.
33. De Zeeuw D, Remuzzi G, Parving HH et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65 (6): 2309–20.
34. Voyaki SM, Staessen JA, Thijs L et al. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. J Hypertens 2001; 19 (3): 509–11. PMID: 11288822
35. Bretzel RG, Bollen CC, Maeser E, Federlin KF. Nephroprotective effects of nitrendipine in hypertensive type I and type II diabetic patients. Am J Kidney Dis 1993; 21 (3): 53–64. PMID: 8503436
36. Kopf D, Schmitz H, Beyer J et al. A double-blind trial of perindopril and nitrendipine in incipient diabetic nephropathy. Diabetes Nutrition and Metabolism 2001; 14 (5): 245–52. PMID: 11806464
37. Van Bortel L, Böhm R, Mooy J et al. Pharmacokinetics of nitrendipine in terminal renal failure. Eur J Clin Pharmacol 1989; 36 (5): 467–71. PMID: 2753064
38. Aronoff GR. Pharmacokinetics of nitrendipine in patients with renal failure: comparison to normal subjects. J Cardiovasc Pharmacol Ther 1984; 6 (7): 974–6. PMID: 6085387
39. Rahn KH, Barenbrock M, Fritschka E et al. Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: a randomised trial. Lancet 1999; 354 (9188): 1415–20. DOI: 10.1016/S0140-6736(99)08421-4
40. Marre M, Garcia Puig J, Kokot F et al. Effect of indapamide SR on microalbuminuria – the NESTOR study (Natrilix SR versus Enalapril Study in Type 2 diabetic hypertensives with micrOalbuminuRia) – rationale and protocol for the main trial. J Hypertension 2003; 21 (1): 19–24. PMID: 12769163
41. Марцевич С.Ю., Суханов Я.В., Белолипецкая В.Г., Кутишенко Н.П. Исследование биоэквивалентности как способ доказательства идентичности оригинального препарата и препарата-дженерика. Рос. кардиол. журн. 2005; 2 (52): 76–8. DOI: 10.15829/1560-4071-2005-2-76-78 / Martsevich S.Iu., Sukhanov Ia.V., Belolipetskaia V.G., Kutishenko N.P. Issledovanie bioekvivalentnosti kak sposob dokazatel'stva identichnosti original'nogo preparata i preparata-dzhenerika. Ros. kardiol. zhurn. 2005; 2 (52): 76–8. DOI: 10.15829/1560-4071-2005-2-76-78 [in Russian]
42. Марцевич С.Ю., Кутишенко Н.П., Деев А.Д., Якусевич В.В. Изучение эффективности и переносимости препарата Индап в сравнении с препаратами Арифон и Арифон ретард у больных мягкой и умеренной артериальной гипертонией, назначаемых как в виде монотерапии, так и в комбинации с ингибиторами АПФ. Многоцентровое, открытое, рандомизированное перекрестное исследование. Рос. кардиол. журн. 2006; 2: 73–7. DOI: 10.15829/1560-4071-2006-2-73-77 / Martsevich S.Iu., Kutishenko N.P., Deev A.D., Iakusevich V.V. Izuchenie effektivnosti i perenosimosti preparata Indap v sravnenii s preparatami Arifon i Arifon retard u bol'nykh miagkoi i umerennoi arterial'noi gipertoniei, naznachaemykh kak v vide monoterapii, tak i v kombinatsii s ingibitorami APF. Mnogotsentrovoe, otkrytoe, randomizirovannoe perekrestnoe issledovanie. Ros. kardiol. zhurn. 2006; 2: 73–7. DOI: 10.15829/1560-4071-2006-2-73-77 [in Russian]
________________________________________________
1. NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet 2017; 389 (10064): 37–55. DOI: 10.1016/S0140-6736(16)31919-5
2. Chow CK, Teo KK, Rangarajan S et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310 (9): 959–68. DOI: 10.1001/jama.2013.184182
3. Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217–23. DOI: 10.1016/S0140-6736(05)70151-3
4. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; (00): 1–98. DOI: 10.1093/eurheartj/ehy339
5. Forouzanfar MH, Liu P, Roth GA et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. JAMA 2017; 317 (2): 165–82. DOI: 10.1001/jama.2016.19043
6. Obshcherossiiskaia obshchestvennaia organizatsiia Assotsiatsiia vrachei obshchei praktiki (semeinykh vrachei). Sektsiia "Sochetannye patologii". Komorbidnaia patologiia v klinicheskoi praktike. Klinicheskie rekomendatsii. Kardiovask. terapiia i profilaktika. 2017; 16 (6): 5–56. DOI: 10.15829/1728-8800-2017-6 [in Russian]
7. Dedov I.I., Shestakova M.V., Vikulova O.K. Epidemiologiia sakharnogo diabeta v Rossiiskoi Federatsii: kliniko-statisticheskii analiz po dannym Federal'nogo registra sakharnogo diabeta. Sakharnyi diabet. 2017; 1 (20): 13–41. [in Russian]
8. IDF Diabetes Atlas, 8th edition. Brussels: International Diabetes Federation; 2017. Available from: https://www.idf.org/e-library/epidemiologyresearch/diabetes-atlas/134-idf-diabetes-atlas-8th-edition. html.
9. Davy KP, Hall JE. Obesity and hypertension: two epidemics or one? Am J Physiol Regul Integr Comp Physiol 2004; 286 (5): 803–13.
10. Morozova T.E. Osobennosti antigipertenzivnoi terapii u patsientov s metabolicheskim sindromom i sakharnym diabetom. Spravochnik poliklinicheskogo vracha. 2006; 8: 25–31. [in Russian]
11. Kaur J. A comprehensive Review on Metabolic Syndrome. Cardiol Res Practice 2014. DOI: org/10.1155/2014/943162
12. Samson SL, Garber AJ. Metabolic syndrome. Endocr Metab Clin North Am 2014; 43 (1): 1–23. PMID: 24582089
13. Rossiiskoe meditsinskoe obshchestvo po arterial'noi gipertonii (RMOAG). Rekomendatsii po vedeniiu bol'nykh metabolicheskim sindromom. Klinicheskie rekomendatsii. M., 2013. [in Russian]
14. Nwaneri C, Cooper H, Bowen-Jones D. Mortality in type 2 diabetes mellitus: magnitude of the evidence from a systematic review and meta-analysis. Br J Diabet Vasc Dis 2013; 4 (13): 192–207. DOI: 10.1177/1474651413495703
15. Sarwar N, Gao P, Seshasai SR et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215–22. DOI: 10.1016/S0140-6736(10)60484-9
16. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979; 241: 2035–8.
17. Miettinen H, Lehto S, Salomaa V et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998; 21 (1): 69–75.
18. Multiple Risk Factor Intervention Trial Research Group: relationship between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial. Prev Med 1986; 15: 254–73.
19. Haffner M, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with 2 diabetes and in nondiabetic subjects with and without prior myocardial infaction. N Eng J Med 1998; 339: 229–34.
20. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53. DOI: 10.1016/S0140-6736(98)07019-6
21. Blokatory kal'tsievykh kanalov: opisanie farmakologicheskoi gruppy v Entsiklopedii RLS. Registr lekarstvennykh sredstv Rossii, RLS. URL: https://www.rlsnet.ru/fg_index_id_215.htm
[in Russian]
22. Fagard RH, Staessen JA. Treatment of isolated systolic hypertension in the elderly: the Syst-Eur trial. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Clin Exp Hypertens 1999; 21 (5–6): 491–7. PMID: 10423075
23. Wang JG, Staessen JA, Gong L, Liu L. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med 2000; 160 (2): 211–20. PMID: 10647760
24. Tuomilehto J, Rastenyte D, Birkenhager WH et al. Effects of calcium channel blockers in older patients with diabetes and systolic hypertension. Eng J Med 1999; 340 (9): 677–84.
25. Farský S, Strišková A, Borčin M. Hypertension Treatment in Patients with Metabolic Syndrome and/or Type 2 Diabetes Mellitus: Analysis of the Therapy Effectivity and the Therapeutic Inertia in Outpatient Study. Card Res Practice 2018; 2018 (1): 8387613. DOI: 10.1155/2018/8387613
26. Rohr G, Reimnitz P, Blanke P. Treatment of hypertensive emergency. Comparison of a new dosage form of the calcium antagonist nitrendipine with nifedipine capsules. Int Care Med 1994; 20 (4): 268–71. PMID: 8046120
27. Mancini M, Marotta T, Ferrara LA. Metabolic neutrality in nitrendipine therapy. J Cardiovasc Pharmacol Ther 1991; 18 (1): 3–30.
28. Ferrara LA, Marotta T. Nitrendipine and metabolic balance. J Cardiovasc Pharmacol Ther 1991; 18 (5): 19–21.
29. Grandinetti O, Feraco E. Middle term evaluation of amlodipine vs. nitrendipine: efficacy, safety and metabolic effects in elderly hypertensive patients. Clin Exp hypertens 1993; 15 (1): 197–210. PMID: 8513310
30. Roush GC, Ernst ME, Kostis JB et al. Head-to-Head Comparisons Hydrochlorothiazide Indapamide and Chlorthalidone: Antihypertensive and Metabolic Effects. Hypertension 2015; 65 (5): 1041–6. DOI: 10.1161/hypertensionaha.114.05021
31. Gerstein HC, Mann JF, Yi Q et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. J Am Med Assoc 2001; 286 (4): 421–6. PMID: 11466120
32. Malhotra R, Nguyen HA, Benavente O et al. Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5: a systematic review and meta-analysis. J Am Med Assoc Int Med 2017; 177: 1498–505.
33. De Zeeuw D, Remuzzi G, Parving HH et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65 (6): 2309–20.
34. Voyaki SM, Staessen JA, Thijs L et al. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. J Hypertens 2001; 19 (3): 509–11. PMID: 11288822
35. Bretzel RG, Bollen CC, Maeser E, Federlin KF. Nephroprotective effects of nitrendipine in hypertensive type I and type II diabetic patients. Am J Kidney Dis 1993; 21 (3): 53–64. PMID: 8503436
36. Kopf D, Schmitz H, Beyer J et al. A double-blind trial of perindopril and nitrendipine in incipient diabetic nephropathy. Diabetes Nutrition and Metabolism 2001; 14 (5): 245–52. PMID: 11806464
37. Van Bortel L, Böhm R, Mooy J et al. Pharmacokinetics of nitrendipine in terminal renal failure. Eur J Clin Pharmacol 1989; 36 (5): 467–71. PMID: 2753064
38. Aronoff GR. Pharmacokinetics of nitrendipine in patients with renal failure: comparison to normal subjects. J Cardiovasc Pharmacol Ther 1984; 6 (7): 974–6. PMID: 6085387
39. Rahn KH, Barenbrock M, Fritschka E et al. Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: a randomised trial. Lancet 1999; 354 (9188): 1415–20. DOI: 10.1016/S0140-6736(99)08421-4
40. Marre M, Garcia Puig J, Kokot F et al. Effect of indapamide SR on microalbuminuria – the NESTOR study (Natrilix SR versus Enalapril Study in Type 2 diabetic hypertensives with micrOalbuminuRia) – rationale and protocol for the main trial. J Hypertension 2003; 21 (1): 19–24. PMID: 12769163
41. Martsevich S.Iu., Sukhanov Ia.V., Belolipetskaia V.G., Kutishenko N.P. Issledovanie bioekvivalentnosti kak sposob dokazatel'stva identichnosti original'nogo preparata i preparata-dzhenerika. Ros. kardiol. zhurn. 2005; 2 (52): 76–8. DOI: 10.15829/1560-4071-2005-2-76-78 [in Russian]
42. Martsevich S.Iu., Kutishenko N.P., Deev A.D., Iakusevich V.V. Izuchenie effektivnosti i perenosimosti preparata Indap v sravnenii s preparatami Arifon i Arifon retard u bol'nykh miagkoi i umerennoi arterial'noi gipertoniei, naznachaemykh kak v vide monoterapii, tak i v kombinatsii s ingibitorami APF. Mnogotsentrovoe, otkrytoe, randomizirovannoe perekrestnoe issledovanie. Ros. kardiol. zhurn. 2006; 2: 73–7. DOI: 10.15829/1560-4071-2006-2-73-77 [in Russian]
Авторы
О.Д.Остроумова*1,2,3, И.В.Голобородова1
1 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1;
2 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 1;
3 ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России – ОСП «Российский геронтологический научно-клинический центр». 129226, Россия, Москва, ул. 1-я Леонова, д. 16
*ostroumova.olga@mail.ru
________________________________________________
O.D.Ostroumova*1,2,3, I.V.Goloborodova1
1 A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1;
2 I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia d. 8, str. 1;
3 N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation – Russian Gerontological Scientific Clinical Center. 129226, Russian Federation, Moscow, ul. 1-ia Leonova, d. 16
*ostroumova.olga@mail.ru